The "when" matters: Evidence from memory markers in the clinical continuum of Alzheimer's disease.
Gonzalo FornoMario Alfredo Parra RodriguezDaniela ThumalaRoque VillagraMauricio CerdaPedro ZitkoAgustin M IbanezPatricia LilloAndrea SlachevaskyPublished in: Neuropsychology (2023)
Our results suggest that the VSTMBT and the FCSRT are sensitive to the clinical continuum of AD. Whereas the former detects changes in the early prodromal stages, the latter is more sensitive to the advanced prodromal stages of AD. These novel tests can aid in the early detection, monitor disease progression and response to treatment, and thus support drug development programs. (PsycInfo Database Record (c) 2023 APA, all rights reserved).